Contact Us

    News

    2024.11.01

    Why IL-2 Still Holds Promise in Therapeutics of Cancer and Autoimmunity

    Aclidineleukin (high-dose IL-2) is the first FDA-approved cancer immunotherapy for metastatic renal cell carcinoma (RCC) and melanoma, but the widespread clinical use of aclidinein has been limited by its short half-life, serious side effects, and simultaneous stimulation of Treg activation. With the breakthrough of studies of immune checkpoint inhibitors, IL-2-based therapeutics has regained widespread attention, […]

    2024.11.01

    CCR8: the Next Promising Immune Checkpoint for Antitumor Drugs Development

    CCR8, as a novel immune checkpoint in tumor microenvironment, was hotly discussed during 2022 AACR conference. Since then, numerous prestigious pharmaceutical corporations have shifted their attention to CCR8, previously almost unknown. You may wonder why CCR8 gave rise to so strong interest of pharmaceutical industry. Just follow us to have a quick review of CCR8, […]

    2024.11.01

    Webinar on Advances in Antibody-Drug Conjugates (ADCs) Development & Preclinical Models

    Join our webinar on June 26th to explore the development and preclinical evaluation of Antibody-Drug Conjugates (ADCs), focusing on their components, mechanisms, and the selection of effective preclinical models for advancing targeted cancer therapies. Date: · Wednesday, June 26th, 2024; 2:00 pm EDT or 11:00 am PDT Webinar Highlights: Understand the components and mechanisms of […]

    Custom Gene-Modified Rat & Mouse Model Service Procedures

    We provide gene editing techniques such as CRISPR/Cas9, transgenic approaches, or gene knockout strategies.

    Researchers can request specific modifications to evaluate phenotypic changes, drug responses, or genetic interactions, facilitating the advancement of biomedical research and therapeutic developments.

    Email Back to top